Eli Lilly & Co LLY Stock Forecast
AI-powered price prediction and analysis for Eli Lilly & Co · Alpha · vs marketSwitch to Total
See LLY's Exact Price Target · Create a free account and follow this stock to unlock its full AI forecast — 3 stocks free.
Price Chart
Key Statistics
About Eli Lilly & Co
Eli Lilly & Co (LLY) operates within the Life Sciences sector, specifically in the Pharmaceutical Preparations industry.
Latest News
Where LLY sits on the market map
Pharmaceutical Preparations Peers
Companies sharing the same SEC industry code, one row per issuer, largest first - a classification match, not a curated list of competitors.
| Company | AI Signal | Market Cap | P/E |
|---|---|---|---|
| LLY Eli Lilly & Co | $1.33T | 45.8x | |
| JNJ Johnson & Johnson | $651.32B | 41.1x | |
| ABBV Abbvie Inc. | $521.11B | 76.2x | |
| MRK Merck & Co., Inc. | $366.03B | 118.7x | |
| NVS Novartis Ag | $308.20B | 9.7x | |
| AZN Astrazeneca Plc | $289.20B | 13.5x | |
| ABT Abbott Laboratories | $191.55B | 30.9x | |
| NVO Novo Nordisk A S | $177.76B | 3.0x | |
| PFE Pfizer Inc | $174.81B | 37.9x | |
| VRTX Vertex Pharmaceuticals Inc / … | $136.87B | 31.5x | |
| BMY Bristol Myers Squibb Co | $128.73B | 13.9x | |
| SNY Sanofi | $106.33B | – | |
| GSK Gsk Plc | $99.12B | 5.4x | |
| REGN Regeneron Pharmaceuticals, Inc. | $98.97B | 21.3x | |
| TAK Takeda Pharmaceutical Co Ltd | $62.51B | 6.0x | |
| TEVA Teva Pharmaceutical Industries Ltd | $47.43B | 84.8x | |
| ONC Beone Medicines Ltd. | $41.07B | 1245.8x | |
| GMAB Genmab A/S | $36.34B | 2.3x | |
| ZTS Zoetis Inc. | $34.37B | 13.7x | |
| RPRX Royalty Pharma Plc | $28.77B | 38.4x | |
| ROIV Roivant Sciences Ltd. | $25.92B | – | |
| UTHR United Therapeutics Corp | $25.57B | 21.4x | |
| INSM Insmed Inc | $23.87B | – | |
| VTRS Viatris Inc | $21.44B | – | |
| ALNY Alnylam Pharmaceuticals, Inc. | $21.14B | 7.4x | |
| ASND Ascendis Pharma A/S | $16.35B | – | |
| BBIO Bridgebio Pharma, Inc. | $14.66B | – | |
| JAZZ Jazz Pharmaceuticals Plc | $13.92B | 70.8x | |
| ELAN Elanco Animal Health Inc | $12.04B | – | |
| RDY Dr Reddys Laboratories Ltd | $11.83B | 15.6x | |
| SMMT Summit Therapeutics Inc. | $11.81B | – | |
| BMRN Biomarin Pharmaceutical Inc | $11.12B | 71.8x | |
| MDGL Madrigal Pharmaceuticals, Inc. | $9.96B | – | |
| TGTX Tg Therapeutics, Inc. | $9.22B | 21.9x | |
| PTGX Protagonist Therapeutics, Inc | $9.02B | 176.4x | |
| CORT Corcept Therapeutics Inc | $8.70B | 90.4x | |
| CYTK Cytokinetics Inc | $8.62B | – | |
| ARWR Arrowhead Pharmaceuticals, Inc. | $8.54B | – | |
| SYRE Spyre Therapeutics, Inc. | $8.42B | – | |
| PRAX Praxis Precision Medicines, Inc. | $7.65B | – | |
| ALKS Alkermes Plc. | $7.53B | 43.6x | |
| ABVX Abivax S.A. | $7.43B | – | |
| IONS Ionis Pharmaceuticals Inc | $7.23B | – | |
| AXSM Axsome Therapeutics, Inc. | $7.12B | – | |
| KNSA Kiniksa Pharmaceuticals International, Plc | $7.09B | 84.1x | |
| AMRX Amneal Pharmaceuticals, Inc. | $6.53B | 61.9x | |
| RYTM Rhythm Pharmaceuticals, Inc. | $6.37B | – | |
| ORKA Oruka Therapeutics, Inc. | $6.32B | – | |
| LGND Ligand Pharmaceuticals Inc | $6.12B | 117.2x | |
| BLTE Belite Bio, Inc | $6.05B | – | |
| MIRM Mirum Pharmaceuticals, Inc. | $5.61B | – | |
| MANE Veradermics, Inc | $5.41B | – | |
| COGT Cogent Biosciences, Inc. | $5.16B | – | |
| PTCT Ptc Therapeutics, Inc. | $5.08B | – | |
| ERAS Erasca, Inc. | $4.91B | – | |
| DNTH Dianthus Therapeutics, Inc. /De/ | $4.60B | – | |
| TVTX Travere Therapeutics, Inc. | $4.41B | – | |
| INDV Indivior Pharmaceuticals, Inc. | $4.17B | 8.6x | |
| EWTX Edgewise Therapeutics, Inc. | $4.14B | – | |
| LQDA Liquidia Corp | $4.03B | 104.8x |
FAQ
Is Eli Lilly & Co a good stock to buy?
Our AI analyzes Eli Lilly & Co daily. Check the signal above for the latest recommendation. Always do your own research before investing.
How accurate are Eli Lilly & Co predictions?
For LLY, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 23.0%, measured on 358 forecast dates between 2022-08-16 and 2026-08-05 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -1.0%, measured on 400 forecast dates between 2022-08-16 and 2026-10-02. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are forecasts updated?
Eli Lilly & Co forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 3, 2026.
Ready to invest smarter? · Join thousands of investors using AI-powered stock predictions
Sign Up FreeLooking for a deeper analysis of Eli Lilly & Co? View full institutional-grade analysis on Intratio →
AI predictions are based on historical patterns and should not be the sole basis for investment decisions. Past performance does not guarantee future results. Always do your own research.